Henry Friedman

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:745-51. 2008
  2. pmc Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells
    Bo Cui
    Departments of Surgery
    J Biomed Res 24:424-35. 2010
  3. pmc Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas
    Daniela A Bota
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center Durham, NC, USA
    Ther Clin Risk Manag 3:707-15. 2007
  4. doi request reprint Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
    Henry S Friedman
    Brain Tumor Center, Duke University, Durham, NC 27710, USA
    J Clin Oncol 27:4733-40. 2009
  5. ncbi request reprint Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke
    H S Friedman
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Med Pediatr Oncol 31:16-8. 1998
  6. ncbi request reprint Irinotecan therapy in adults with recurrent or progressive malignant glioma
    H S Friedman
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 17:1516-25. 1999
  7. ncbi request reprint DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
    H S Friedman
    Department of Surgery, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 16:3851-7. 1998
  8. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
  9. ncbi request reprint O6-benzylguanine-mediated enhancement of chemotherapy
    Henry S Friedman
    Departments of Surgery, Pathology and Medicine, Duke University Medical Center, Room 047, Baker House, Trent Drive, Durham, North Carolina 27710, USA
    Mol Cancer Ther 1:943-8. 2002
  10. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009

Research Grants

  1. ZD1839 Therapy of Glioblastoma Multiforme
    Henry Friedman; Fiscal Year: 2002
  2. PEDIATRIC BRAIN TUMOR CLINICAL TRIALS CONSORTIUM
    Henry Friedman; Fiscal Year: 2003
  3. Regional AGT Depeltion of CNS and Leptomeningeal Tumors
    Henry Friedman; Fiscal Year: 2005
  4. Temodar Resistance in CNS Tumors
    Henry Friedman; Fiscal Year: 2008

Detail Information

Publications91

  1. pmc Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:745-51. 2008
    ..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence...
  2. pmc Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells
    Bo Cui
    Departments of Surgery
    J Biomed Res 24:424-35. 2010
    ..We anticipate that our findings will lead to more studies that seek to further define the role of DDR in ultimately determining the fate of a tumor cell in response to TMZ and other DNA methylators...
  3. pmc Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas
    Daniela A Bota
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center Durham, NC, USA
    Ther Clin Risk Manag 3:707-15. 2007
    ....
  4. doi request reprint Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
    Henry S Friedman
    Brain Tumor Center, Duke University, Durham, NC 27710, USA
    J Clin Oncol 27:4733-40. 2009
    ..We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial...
  5. ncbi request reprint Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke
    H S Friedman
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Med Pediatr Oncol 31:16-8. 1998
    ....
  6. ncbi request reprint Irinotecan therapy in adults with recurrent or progressive malignant glioma
    H S Friedman
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 17:1516-25. 1999
    ..To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with progressive, persistent, or recurrent malignant glioma...
  7. ncbi request reprint DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
    H S Friedman
    Department of Surgery, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 16:3851-7. 1998
    ....
  8. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  9. ncbi request reprint O6-benzylguanine-mediated enhancement of chemotherapy
    Henry S Friedman
    Departments of Surgery, Pathology and Medicine, Duke University Medical Center, Room 047, Baker House, Trent Drive, Durham, North Carolina 27710, USA
    Mol Cancer Ther 1:943-8. 2002
    ..These results suggest that a Phase I trial of CPT-11 plus temozolomide plus O6-BG in AGT-positive tumors may be an important intervention to maximize the therapeutic benefits of the combination of CPT-11 and temozolomide...
  10. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
    ..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials...
  11. ncbi request reprint Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)
    Amy B Heimberger
    Department of Surgery, Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 8:3496-502. 2002
    ..On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII...
  12. ncbi request reprint Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma
    Tomio Ueno
    Department of Surgery, Box 3118 Medical Center, Duke University Medical Center, Durham, NC 27710, USA
    Am J Surg 188:532-7. 2004
    ..Regional infusion therapy with melphalan (LPAM) is an accepted treatment for advanced extremity melanoma. However, much room exists for improving the therapeutic index of this type of therapy...
  13. ncbi request reprint The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors
    Henry S Friedman
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 97:2359-62. 2003
    ..Studies currently are addressing the role of O(6)-alkylguanine-DNA alkyltransferase (AGT) in reducing the benefits of combining CPT-11 with temozolomide and the potential therapeutic gain from utilizing an inhibitor of AGT...
  14. ncbi request reprint Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study
    Gamal Akabani
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    J Nucl Med 46:1042-51. 2005
    ....
  15. pmc Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
    ..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)...
  16. pmc Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
    Sith Sathornsumetee
    Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
    J Clin Oncol 26:271-8. 2008
    ....
  17. pmc Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience
    Christopher D Turner
    The Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 4:102-8. 2002
    ..Ongoing studies will demonstrate if activity of CPT-11 can be enhanced when combined with alkylating agents, including carmustine and temozolomide...
  18. pmc Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
    Patrick J Killela
    Department of Pathology, Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center at Duke, and Pediatric Brain Tumor Foundation Institute at Duke, Durham, NC, USA
    Oncotarget 5:1515-25. 2014
    ..Analyzing gliomas based on their genetic signatures allows for the stratification of these patients into distinct cohorts, with unique prognosis and survival. ..
  19. pmc Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
    Michael A Badruddoja
    Duke University Medical Center, Brain Tumor Center, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 9:70-4. 2007
    ..Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme...
  20. ncbi request reprint A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth
    Qing Shi
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Carcinog 46:488-96. 2007
    ..TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. Together, these data demonstrate the potential benefit of TAE226 for glioma therapy...
  21. ncbi request reprint SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility
    Mark D Hjelmeland
    Division of Neurology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 3:737-45. 2004
    ..Together, our results suggest that small molecule inhibitors of TGF-beta receptors may offer a novel therapy for malignant gliomas by reducing cell proliferation, angiogenesis, and motility...
  22. ncbi request reprint Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme
    Chris A Learn
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 10:3216-24. 2004
    ..Determination of how this differential inhibition occurs may be important to patient selection and treatment criteria, as well as the design of future therapeutics for glioblastoma multiforme...
  23. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  24. ncbi request reprint Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents
    Yasunori Yoshimoto
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710, USA
    Mol Cancer Ther 6:1492-500. 2007
    ..Our observations also point out the limited ability of analysis of the GST/glutathione pathway to predict response to chemotherapies like melphalan whose resistance is primarily mediated through a complex mechanism of detoxification...
  25. ncbi request reprint Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts
    Ganesan Vaidyanathan
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:1868-76. 2003
    ....
  26. pmc A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells
    Meryem Bektas
    Department of Pathology, Duke University Medical Center, Durham, NC, USA
    Cancer Chemother Pharmacol 64:1053-8. 2009
    ..However, virtually all tumors become resistant to TMZ. Therefore, new drug targets are necessary. In this study, we investigated whether inhibiting sphingosine kinase could induce cell death in TMZ-resistant GBM cells...
  27. doi request reprint Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy
    Mary Lou Affronti
    Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
    Cancer 115:3501-11. 2009
    ..The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chemotherapy was investigated...
  28. pmc The genetic landscape of anaplastic astrocytoma
    Patrick J Killela
    Department of Pathology, Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center at Duke, and Pediatric Brain Tumor Foundation Institute at Duke, Durham, NC
    Oncotarget 5:1452-7. 2014
    ..This study suggests genetic signatures will be useful for the classification of gliomas. ..
  29. pmc IDH1 and IDH2 mutations in gliomas
    Hai Yan
    Department of Pathology, Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 360:765-73. 2009
    ....
  30. ncbi request reprint The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion
    Anita B Hjelmeland
    Department of Surgery, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 6:2449-57. 2007
    ..These data suggest that the combination of LBT613 and RAD001 reduces glioma cell proliferation and invasion and support examination of the combination of RAF and TOR inhibitors for the treatment of human glioblastoma patients...
  31. ncbi request reprint Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine
    Tomio Ueno
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, NC 27710, USA
    Mol Cancer Ther 5:732-8. 2006
    ..Clinical trials using chemotherapy modulation may improve response rates in future regional infusion and perfusion drug trials...
  32. ncbi request reprint Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion
    Anita Lal
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 62:3335-9. 2002
    ..Furthermore, inhibitors of EGFR (OSI-774 and Tyrphostin AG1478) selectively down-regulated these molecular effectors in glioblastoma cells, eliminating enhanced invasion...
  33. ncbi request reprint Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity
    Sae Hee Ko
    Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:289-97. 2006
    ..The aim of this study was to determine whether hyperthermia could further augment the efficacy of temozolomide, an alkylating agent, against melanoma and improve its therapeutic index in a rat model of isolated limb infusion...
  34. ncbi request reprint Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft
    C Lynn Cheng
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Mol Cancer Ther 4:1364-8. 2005
    ..9 and 45.7 days, respectively. These results suggest that inhibition of PARP may increase the efficacy of temozolomide in the treatment of malignant gliomas, particularly in tumors deficient in DNA mismatch repair...
  35. ncbi request reprint Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer
    Peter M Grossi
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:5514-20. 2003
    ..Direct intracerebral microinfusion (ICM) is a technique that bypasses this blood-brain barrier and allows for a greater delivery of drugs directly into intracerebral tumors...
  36. ncbi request reprint Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations
    Manny D Bacolod
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Mol Cancer Ther 3:1127-35. 2004
    ..These data suggest that the clonal selection of AGT mutants during treatment with O6-BG plus an alkylator may produce resistance to this intervention in clinical settings...
  37. pmc Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma
    Jill A Maxwell
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:4859-68. 2008
    ..The purpose of this study was to determine the role of MMR deficiency in mediating resistance in samples from patients with both newly diagnosed malignant gliomas and those who have failed temozolomide therapy...
  38. ncbi request reprint Screening for distress in patients with brain cancer using the NCCN's rapid screening measure
    Stephen T Keir
    The Tug McGraw Research Center, The Preston Robert Tisch Brain Tumor Center at Duke, 3624 DUMC, Durham, NC 27710, USA
    Psychooncology 17:621-5. 2008
    ..Using the National Comprehensive Cancer Network's Distress Thermometer, we evaluated the extent and sources of distress within a population of patients with brain cancer...
  39. ncbi request reprint Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
    ..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan...
  40. pmc Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 10:330-40. 2008
    ..A subsequent phase 2 study is required to further evaluate the efficacy of this regimen for this patient population...
  41. pmc Experience with irinotecan for the treatment of malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 11:80-91. 2009
    ..Toxicities associated with irinotecan have been manageable; the most important dose-limiting toxicities are neutropenia and diarrhea. Irinotecan-based chemotherapy of malignant glioma merits further study...
  42. ncbi request reprint Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 23:7178-87. 2005
    ..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG...
  43. doi request reprint Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma
    Christina K Augustine
    Medical Center Duke University Medical Center, Durham, NC 27710, USA
    Mol Cancer Ther 9:779-90. 2010
    ..Mol Cancer Ther; 9(4); 779-90. (c)2010 AACR...
  44. doi request reprint Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme
    Michael J Paldino
    Duke University Medical Center, Department of Radiology, Durham, North Carolina 27710, USA
    J Magn Reson Imaging 29:1199-205. 2009
    ..To quantify the repeatability of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in patients with glioblastoma multiforme...
  45. pmc Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients
    Stephanie L Perry
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:129-34. 2009
    ..Tinzaparin at a fixed prophylactic dose is safe and may decrease the incidence of thromboembolic complications in brain tumor patients...
  46. pmc Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
    David A Reardon
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2188-98. 2009
    ....
  47. doi request reprint Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing
    Lee W Jones
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 94:79-85. 2009
    ..We conducted a pilot study to explore the feasibility and clinical utility of functional capacity testing to assess physical functioning in recurrent primary malignant glioma patients...
  48. doi request reprint Genomic and molecular profiling predicts response to temozolomide in melanoma
    Christina K Augustine
    Department of Surgery, and Duke Institute for Genome Sciences and Policy, Duke University Medical Center and Durham VA Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:502-10. 2009
    ..The goal of this study was to identify molecular and/or genetic markers that correlate with, and could be used to predict, response to temozolomide-based treatment regimens and that reflect the intrinsic properties of a patient's tumor...
  49. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008
    ..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma...
  50. doi request reprint Distress persists in long-term brain tumor survivors with glioblastoma multiforme
    Stephen T Keir
    Surgery Department, Tug McGraw Research Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA
    J Cancer Surviv 2:269-74. 2008
    ..However, little is known about the psychological correlates of this disease. To address this issue we investigated distress and its sources in long-term survivors (LTS) of this disease...
  51. pmc An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Cancer Ther 8:2773-9. 2009
    ..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy...
  52. pmc Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Nucl Med 49:30-8. 2008
    ..The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors...
  53. ncbi request reprint O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines
    Stewart P Johnson
    Department of Surgery, Duke University Medical Center, Box 2616, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 60:883-9. 2007
    ..Previous studies have suggested that uptake of O(4)-BFA is mediated by the folate receptor (FR), and, thus, its use may be limited to cells expressing FR...
  54. ncbi request reprint Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
    ..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma...
  55. ncbi request reprint Chemotherapy and novel therapeutic approaches in malignant glioma
    Annick Desjardins
    The Brain Tumor Center, Department of Pediatrics, Duke University Medical Center, 047 Baker House, Trent Drive, Box 3624, Durham, NC 27710, USA
    Front Biosci 10:2645-68. 2005
    ..In this article, we review the past, present and future treatments of malignant gliomas with a special interest on chemotherapy, resistance mechanisms and tyrosine kinase inhibitors...
  56. ncbi request reprint Recent advances in the treatment of pediatric brain tumors
    Sri Gururangan
    The Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, USA
    Oncology (Williston Park) 18:1649-61; discussion 1662, 1665-6, 1668. 2004
    ..Ongoing clinical trials will determine whether these novel treatment modalities will improve outcomes for children with brain tumors...
  57. pmc Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:145-53. 2004
    ....
  58. pmc Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:134-44. 2004
    ..9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic...
  59. ncbi request reprint Irinotecan: promising activity in the treatment of malignant glioma
    David A Reardon
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Oncology (Williston Park) 17:9-14. 2003
    ..Other investigative directions include studies of irinotecan plus temozolomide and O6-benzylguanine (O6-BG) to assess the ability of O6-BG to maximize the therapeutic benefits of irinotecan combined with temozolomide...
  60. ncbi request reprint Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines
    Henry S Friedman
    Department of Neuro Oncology, Duke University Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer Treat Res 112:199-209. 2002
  61. ncbi request reprint O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase
    Ganesan Vaidyanathan
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Bioconjug Chem 15:402-8. 2004
    ..After intratumoral injection of [(131)I]IBG in the same xenograft model, the uptake in tumors that were depleted of AGT by BG treatment (165.8 +/- 27.5% ID/g) was about 60% of that in control mice (272.4 +/- 48.2% ID/g; p < 0.05)...
  62. ncbi request reprint Molecular markers of prognosis in astrocytic tumors
    Ahmed Rasheed
    Department of Pathology, Duke University Medical Center, 3156, Durham, NC 27710, USA
    Cancer 94:2688-97. 2002
    ..To date, only age and histologic grade stand out as independent predictors of survival. There is now increased interest in the use of molecular markers as objective standards against which to establish diagnosis and grade...
  63. ncbi request reprint Phase II study of carboplatin in children with progressive low-grade gliomas
    Sridharan Gururangan
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2951-8. 2002
    ..To assess the rate of tumor response and activity of carboplatin in stabilizing the growth of progressive low-grade gliomas...
  64. ncbi request reprint Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    ....
  65. ncbi request reprint Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma
    Sridharan Gururangan
    The Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 77:207-12. 2006
    ..We performed a retrospective study of patients with diffuse pontine glioma (DPG) who suffered neuraxis metastasis (NM) and characterized the incidence, clinical features, radiologic findings, and patterns of disease dissemination...
  66. ncbi request reprint Exercise interest and preferences among patients diagnosed with primary brain cancer
    Lee W Jones
    Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 15:47-55. 2007
    ..Secondary aims were to examine potential differences in participant's interest and preferences by exercise behavior and select demographic/medical variables...
  67. ncbi request reprint Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  68. ncbi request reprint Stress and intervention preferences of patients with brain tumors
    Stephen T Keir
    The Tug McGraw Center for Quality of Life Supportive Care Research, The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, P O Box 3624, Durham, NC 27710, USA
    Support Care Cancer 14:1213-9. 2006
    ..To design effective stress reduction interventions, it is essential to have an understanding of the beliefs, past experiences, and preferences concerning stress reduction techniques and programs among patients with BTs...
  69. ncbi request reprint Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin
    Hidenobu Ochiai
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neurol Med Chir (Tokyo) 46:485-9; discussion 489-90. 2006
    ..005). These results suggest that intrathecal treatment with 9NC may be useful for patients with GBM neoplastic meningitis...
  70. ncbi request reprint AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
    Sith Sathornsumetee
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:8722-30. 2006
    ....
  71. pmc Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor
    Tatsunori Okamura
    Department of Surgery, Duke Comprehensive Cancer Center, Duke University, Durham, North Carolina 27710, USA
    J Biol Chem 284:16979-89. 2009
    ....
  72. pmc TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
    Patrick J Killela
    Pediatric Brain Tumor Foundation Institute at Duke, and Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:6021-6. 2013
    ....
  73. ncbi request reprint Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine
    Sriram Shankar
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 33:399-407. 2006
    ..AcO)2-[131I]IBdG, a peracetylated derivative of IBdG, also was investigated as an alternative agent...
  74. ncbi request reprint The pediatric preclinical testing program: description of models and early testing results
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 49:928-40. 2007
    ..Here, we describe the characteristics of the in vivo tumor panels and report results for the in vivo evaluation of two standard agents, vincristine and cyclophosphamide...
  75. pmc Molecular characterization of the pediatric preclinical testing panel
    Geoffrey Neale
    Hartwell Center of Bioinformatics and Biotechnology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 14:4572-83. 2008
    ..Identifying novel therapeutic agents for the treatment of childhood cancers requires preclinical models that recapitulate the molecular characteristics of their respective clinical histotypes...
  76. ncbi request reprint The fallacy of single-agent chemotherapy for cancer
    Henry S Friedman
    J Clin Oncol 25:3550; author reply 3550-1. 2007
  77. ncbi request reprint Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases
    Matthew J McGirt
    Duke University School of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosurg 96:941-5. 2002
    ....
  78. ncbi request reprint Stress and long-term survivors of brain cancer
    Stephen T Keir
    The Tug McGraw Research Center, The Preston Robert Tisch Brain Tumor Center, Duke Surgery Department, Division of Neuro Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Support Care Cancer 15:1423-8. 2007
    ..As a result, health care providers are faced with new challenges to address the need for psychosocial support in this population...
  79. ncbi request reprint Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study
    Charles G Eberhart
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer 94:552-60. 2002
    ....
  80. ncbi request reprint Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect
    Matthew J McGirt
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosurg 98:14-20. 2003
    ..The prognostic value of differentiating between recurrent malignant glioma and a lesion due to radiation effect by performing stereotactic biopsy has not been assessed. Thus, this study was undertaken to determine such value...
  81. ncbi request reprint Phase II trial of temozolomide in patients with progressive low-grade glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:646-51. 2003
    ..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma...
  82. ncbi request reprint High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas
    Sridharan Gururangan
    Brain Tumor Center at Duke and the Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:2187-91. 2003
    ..We evaluated the usefulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) in patients with newly diagnosed pineoblastoma (PBL)...
  83. ncbi request reprint Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
    ..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients...
  84. ncbi request reprint A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group
    Murali M Chintagumpala
    Baylor College of Medicine, 6621 Fannin, CC 1510 00, Houston, TX, USA
    J Neurooncol 77:193-8. 2006
    ..Future trials should consider strategies to overcome the resistance mechanisms in children with high-grade glioma...
  85. ncbi request reprint ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
    ..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies...
  86. ncbi request reprint Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1478-86. 2005
    ..The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)...
  87. ncbi request reprint Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  88. doi request reprint Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study
    Sridharan Gururangan
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:1124-30. 2008
    ..VNP40101M (Cloretazine), a novel DNA alkylating agent, was evaluated in a phase I study in children with recurrent brain tumors...
  89. ncbi request reprint Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts
    Markos Leggas
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 8:3000-7. 2002
    ....
  90. ncbi request reprint Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report
    Alberto Broniscer
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Clin Cancer Res 13:6712-8. 2007
    ..To estimate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of escalating doses of temozolomide combined with O(6)-benzylguanine in patients < or =21 years with recurrent brain tumors...
  91. ncbi request reprint Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:1253-9. 2007
    ..This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma...

Research Grants4

  1. ZD1839 Therapy of Glioblastoma Multiforme
    Henry Friedman; Fiscal Year: 2002
    ....
  2. PEDIATRIC BRAIN TUMOR CLINICAL TRIALS CONSORTIUM
    Henry Friedman; Fiscal Year: 2003
    ..abstract_text> ..
  3. Regional AGT Depeltion of CNS and Leptomeningeal Tumors
    Henry Friedman; Fiscal Year: 2005
    ..To define the role of intrathecal AGT inhibitors in enhancing system or intrathecal temozolomide therapy of neoplastic meningitis. ..
  4. Temodar Resistance in CNS Tumors
    Henry Friedman; Fiscal Year: 2008
    ..abstract_text> ..